BioAegis Therapeutics Secures FDA Fast Track Designation for Lead ARDS Therapy
Wednesday, June 18, 2025
BioAegis Therapeutics has received Fast Track designation from the US Food and Drug Administration (FDA) for its lead candidate, recombinant human plasma gelsolin (rhu-pGSN), aimed at treating acute respiratory distress syndrome (ARDS).
ARDS is a critical respiratory condition characterised by severe lung inflammation and fluid build-up, often requiring intensive care. It affects over 500,000 individuals annually in the United States alone and accounts for around 10% of all ICU admissions. Despite its high mortality rate—estimated at 40%—there are currently no approved pharmacological treatments for the condition, highlighting a significant unmet medical need.
The designation is intended to accelerate the development of treatments for serious conditions with limited existing therapies.
Recombinant plasma gelsolin is based on a naturally occurring immune regulatory protein, which plays a key role in restoring immune balance without compromising the body’s defence mechanisms. BioAegis is currently advancing a global Phase 2b trial involving 600 patients to assess the safety and efficacy of rhu-pGSN in individuals with moderate to severe ARDS (NCT05947955).
The FDA Fast Track designation allows for more frequent communication with the regulatory body and can lead to a quicker review process. It may also open the door for rhu-pGSN to be accessed through the FDA’s Expanded Access or Compassionate Use programmes, potentially offering a treatment option to patients outside of clinical trials.
The Fast Track status is expected to support the timely advancement of rhu-pGSN, offering hope for a new treatment option in an area with few alternatives.
Source: globenewswire.com
